President of Research and Development
Infinity Pharmaceuticals, Inc.
Cambridge, Massachusetts, USA
Dr. Julian Adams is the President of Research and Development of Infinity Pharmaceuticals, Inc. Dr. Adams received a B.S. from McGill University and a Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. Prior to joining Infinity, Dr. Adams was the Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of VELCADE®, a proteasome inhibitor for cancer therapy. Earlier in his career, Dr. Adams served in various positions at LeukoSite, ProScript, Inc., and Boehringer Ingelheim, where he successfully discovered the drug Viramune® for HIV.
Dr. Adams is an inventor of over 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals, and is the editor of Proteasome Inhibition in Cancer Therapy published. He has received many awards, including the 2001 Ribbon of Hope Award for VELCADE® from the International Myeloma Foundation and the AACR-Bruce F. Cain Memorial Award.